边做边流奶水的人妻_2020最新无码福利视频_国产精品白丝喷水在线观看_日本伊人精品一区二区三区_亚洲综合成人AⅤ在线观看_无套内射CHINESEHD_可播放的亚洲男同网站_高大丰满熟妇丰满的大白屁股

您好,歡迎光臨上海雅吉生物商城!
工作時間:9:00-18:00
全國服務熱線:021-34661276

Ultra-LEAF™ Purified anti-human CD3 Antibody

訂購數(shù)量:
規(guī)格
價格庫存
訂購熱線:021-34661276
我要詢價
  • 商品詳情
  • 售后服務
  • 相關文獻

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
0.2 ?m filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxin level is <0.01 EU/?g of the protein (<0.001 ng/?g of the protein) as determined by the LAL test.
Preparation
The Ultra-LEAF? (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF? solution contains no preservative; handle under aseptic conditions.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 ?g per million cells in 100 ?l volume or 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  2. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  3. Mancuso RV, et al. 2020. British Journal of Pharmacology. 177(12):2696-2711.. PubMed
  4. Babin L, et al. 2022. Mol Cancer. 21:65. PubMed
  5. Rieder SA, et al. 2020. Cell Mol Immunol. . PubMed
  6. Hsiue EH, et al. 2021. Science. 371:. PubMed
  7. Liu Y, et al. 2021. Immunol Cell Biol. 99:697. PubMed
  8. Yuan X, et al. 2022. J Extracell Vesicles. 11:e12235. PubMed
  9. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
  10. Nicolas P, et al. 2022. J Exp Med. 219:. PubMed
  11. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  12. Bak RO, et al. 2018. Nat Protoc. 13:358. PubMed
  13. Wang J, et al. 2022. Nat Commun. 13:6866. PubMed
  14. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  15. Liu W, et al. 2021. J Biol Chem. 297:101102. PubMed
  16. Fang F, et al. 2022. JCI Insight. 7:. PubMed
  17. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  18. Chen X, et al. 2021. Theranostics. 11:3392. PubMed
  19. Campos Carrascosa L, et al. 2020. J Immunother Cancer. 8:00. PubMed
  20. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  21. Yan B, et al. 2021. Sci Immunol. 6: . PubMed
  22. Jung Y, et al. 2021. Nat Commun. 12:3872. PubMed
  23. Camviel N, et al. 2022. J Immunother Cancer. 10:. PubMed
  24. Warmuth S, et al. 2022. Oncoimmunology. 10:2004661. PubMed
  25. Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
  26. Smith CM, et al. 2021. Biochem J. 478:3331. PubMed
  27. Saragovi A, et al. 2020. Elife. 9:00. PubMed
  28. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  29. Han K, et al. 2021. Nat Metab. 3:318. PubMed
  30. Kinloch NN, et al. 2021. Nat Commun. 12:165. PubMed
  31. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  32. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  33. Dahal S, et al. 2022. Retrovirology. 19:18. PubMed
  34. Collins DR, et al. 2021. Immunity. 54:2372. PubMed
  35. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  36. Ren X, et al. 2022. STAR Protoc. 3:101818. PubMed
  37. Pan W, et al. 2020. JCI Insight. 5:00. PubMed
  38. Sekine T, et al. 2020. Cell. 183:158. PubMed
  39. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  40. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  41. Feng Y, et al. 2022. Life (Basel). 12:. PubMed
  42. Thakkar D, et al. 2022. J Immunother Cancer. 10:. PubMed
  43. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  44. Correnti CE, et al. 2020. Nat Struct Mol Biol. 27:342. PubMed
  45. Xie X, et al. 2021. Front Immunol. 12:625808. PubMed
  46. Hurov K, et al. 2021. J Immunother Cancer. 9:. PubMed
  47. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  48. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  49. Jiang J, et al. 2021. Front Immunol. 12:785549. PubMed
  50. Hu BS, et al. 2020. Cancer Cell Int. 1.189583333. PubMed
  51. Wang J, et al. 2019. Sci Rep. 9:8445. PubMed
  52. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  53. Winheim E, et al. 2021. PLoS Pathog. 17:e1009742. PubMed
  54. Clayton KL, et al. 2021. Cell Host Microbe. 29(3):435-447.e9. PubMed
  55. Hu Y, et al. 2016. J Exp Med. 213: 2759 - 2772. PubMed
  56. Zhu P, et al. 2022. Cell Commun Signal. 20:121. PubMed
  57. Gorchs L, et al. 2022. Cancers (Basel). 14:. PubMed
  58. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  59. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
  60. de Haan L, et al. 2021. Int J Mol Sci. 22:. PubMed
RRID
AB_11147370 (BioLegend Cat. No. 317325) AB_11150592 (BioLegend Cat. No. 317326) AB_2571994 (BioLegend Cat. No. 317347) AB_2571995 (BioLegend Cat. No. 317348) AB_2749888 (BioLegend Cat. No. 317349) AB_2749889 (BioLegend Cat. No. 317350)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org
我要詢價
*聯(lián)系方式:
(可以是QQ、MSN、電子郵箱、電話等,您的聯(lián)系方式不會被公開)
*內容:


微信客服
掃一掃立即咨詢


微信客服
掃一掃立即咨詢

銷售電話:

021-34661275

021-34661276

15301693058